Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manabu Morimoto

Showing results (121-130 of 160) with videos related to

Pageof 16
Sort By:
Diagnostics (Basel, Switzerland)|January 25, 2025
Diagnostic Accuracy of Detective Flow Imaging Endoscopic Ultrasonography for Evaluating Blood Flow Within Mural Nodules of Intraductal Papillary Mucinous NeoplasmsKazuki Endo, Haruo Miwa, Kazuya Sugimori, et al.
The Oncologist|October 3, 2020
Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study)Naohiro Okano, Junji Furuse, Makoto Ueno, et al.
BMC Cancer|October 17, 2019
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Manabu Morimoto, Satoshi Kobayashi, et al.
Cancer Chemotherapy and Pharmacology|October 10, 2014
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancerToru Aoyama, Yusuke Katayama, Masaaki Murakawa, et al.
Liver Cancer|August 20, 2025
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 TrialMasatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, et al.
Journal of Digestive Diseases|December 16, 2014
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weightingMasaaki Kondo, Manabu Morimoto, Tomohiro Ishii, et al.
Anticancer Research|August 1, 2018
The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant ChemotherapyToru Aoyama, Naoto Yamamoto, Mariko Kamiya, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2015
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patientsToru Aoyama, Yusuke Katayama, Masaaki Murakawa, et al.
Journal of Cancer Research and Therapeutics|December 31, 2020
The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapyToru Aoyama, Naoto Yamamoto, Mariko Kamiya, et al.
Oncology Letters|August 10, 2017
Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapyMasaaki Murakawa, Toru Aoyama, Yohei Miyagi, et al.
Pageof 16

Showing results (121-130 of 160) with videos related to

Sort By:
Pageof 16
Diagnostics (Basel, Switzerland)|January 25, 2025
Diagnostic Accuracy of Detective Flow Imaging Endoscopic Ultrasonography for Evaluating Blood Flow Within Mural Nodules of Intraductal Papillary Mucinous NeoplasmsKazuki Endo, Haruo Miwa, Kazuya Sugimori, et al.
The Oncologist|October 3, 2020
Multicenter Phase II Trial of Axitinib Monotherapy for Gemcitabine-Based Chemotherapy Refractory Advanced Biliary Tract Cancer (AX-BC Study)Naohiro Okano, Junji Furuse, Makoto Ueno, et al.
BMC Cancer|October 17, 2019
Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trialMasaaki Kondo, Manabu Morimoto, Satoshi Kobayashi, et al.
Cancer Chemotherapy and Pharmacology|October 10, 2014
Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancerToru Aoyama, Yusuke Katayama, Masaaki Murakawa, et al.
Liver Cancer|August 20, 2025
First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 TrialMasatoshi Kudo, Masafumi Ikeda, Hiroshi Aikata, et al.
Journal of Digestive Diseases|December 16, 2014
Hepatic arterial infusion chemotherapy with cisplatin and sorafenib in hepatocellular carcinoma patients unresponsive to transarterial chemoembolization: a propensity score-based weightingMasaaki Kondo, Manabu Morimoto, Tomohiro Ishii, et al.
Anticancer Research|August 1, 2018
The Lymph Node Ratio Is an Independent Prognostic Factor in Pancreatic Cancer Patients Who Receive Curative Resection Followed by Adjuvant ChemotherapyToru Aoyama, Naoto Yamamoto, Mariko Kamiya, et al.
Cancer Chemotherapy and Pharmacology|March 31, 2015
Safety and feasibility of S-1 adjuvant chemotherapy for pancreatic cancer in elderly patientsToru Aoyama, Yusuke Katayama, Masaaki Murakawa, et al.
Journal of Cancer Research and Therapeutics|December 31, 2020
The age-adjusted Charlson comorbidity index is an independent prognostic factor in pancreatic cancer patients who receive curative resection followed by adjuvant chemotherapyToru Aoyama, Naoto Yamamoto, Mariko Kamiya, et al.
Oncology Letters|August 10, 2017
Clinical implications of dihydropyrimidine dehydrogenase expression in patients with pancreatic cancer who undergo curative resection with S-1 adjuvant chemotherapyMasaaki Murakawa, Toru Aoyama, Yohei Miyagi, et al.
Pageof 16